Terminated PHASE1/PHASE2 INTERVENTIONAL NCT00003552

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma

Phase I/II Study of HLA-Matched Peripheral Blood Mobilized Hematopoietic Progenitor Cell Transplantation Followed by Allogeneic T-cell Infusion as Adoptive Immunotherapy in Patients With Metastatic Melanoma

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Conditions Recurrent Melanoma Stage IV Melanoma

Interventions allogeneic lymphocytes anti-thymocyte globulin cyclophosphamide fludarabine

Updated 6 times since 2017 Last updated: Mar 1, 2024 Started: Jan 31, 1999 Completion: Oct 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from National Heart, Lung, and Blood Institute (NHLBI)

See all terminations from National Heart, Lung, and Blood Institute (NHLBI)

Other Recurrent Melanoma trials with similar outcome

Browse all Recurrent Melanoma trials

This PHASE1/PHASE2 trial investigates Recurrent Melanoma and Stage IV Melanoma and is currently terminated or withdrawn. National Heart, Lung, and Blood Institute (NHLBI) leads this study, which shows 6 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2024 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
Jan 2021 — Apr 2024 [monthly]

Terminated PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1_PHASE2

First recorded

Jan 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Heart, Lung, and Blood Institute (NHLBI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States